SCHEMBL6679185

SCHEMBL6679185

Cn1c2c(c(=O)n(Cc3ccccc3)c1=O)C=C(C(=O)O)CS2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.45
PKM P14618 2/20 0.45
RAB9A P51151 1/20 0.45
MAPK1 P28482 1/20 0.43
ALDH1A1 P00352 4/20 0.42
LMNA P02545 2/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
LGMN Q99538 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
ADORA2B P29275 1/20 0.40
MAPT P10636 2/20 0.40
GAA P10253 1/20 0.40
HIF1A Q16665 1/20 0.40
CYP3A4 P08684 1/20 0.40
HPGD P15428 1/20 0.40
CCNB2 O95067 1/20 0.39
CDK1 P06493 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6663839 0.85 ALDH1A1 (0.36) SMN1; SMN2PKMRAB9AALDH1A1MMP13
SCHEMBL6666868 0.84 P2RX7 (0.31) SMN1; SMN2PKMRAB9A
SCHEMBL6684214 0.80 THRB (0.43) SMN1; SMN2ALDH1A1MEN1KMT2AADORA2B
SCHEMBL6664200 0.79 MAPT (0.47) RAB9AALDH1A1MAPTHPGDMMP13
SCHEMBL6681995 0.78 SMN1; SMN2 (0.48) SMN1; SMN2PKMRAB9AALDH1A1LMNA
SCHEMBL6668311 0.77 SMN1; SMN2 (0.45) SMN1; SMN2PKMRAB9AALDH1A1LMNA
SCHEMBL7061008 0.77 SMN1; SMN2 (0.45) SMN1; SMN2PKMRAB9AALDH1A1LMNA
SCHEMBL6662621 0.76 ALDH1A1 (0.43) SMN1; SMN2ALDH1A1LMNAMEN1KMT2A
SCHEMBL6678347 0.69 ALDH1A1 (0.43) SMN1; SMN2PKMRAB9AALDH1A1LMNA
SCHEMBL6677958 0.69 SMN1; SMN2 (0.44) SMN1; SMN2PKMRAB9AMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-11-11 US disclosed
WO-2004014921-A1 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP25 SMN1; SMN2 682/4885PKM 2081/4885RAB9A 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.